Medigene NA O.N. (MDG2)

Vienna
Currency in EUR
1.550
+0.030(+1.97%)
Closed
MDG2 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
1.5481.550
52 wk Range
0.9965.128
Key Statistics
Edit
Bid/Ask
1.46 / 1.644
Prev. Close
1.52
Open
1.55
Day's Range
1.548-1.55
52 wk Range
0.996-5.128
Volume
-
Average Volume (3m)
1.95K
1-Year Change
-48.53%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MDG2 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Medigene NA O.N. Company Profile

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company’s end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its lead product includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications. The company also develops MDG2011, MDG2021, MDG2012, MDG20XX, and MDG10xx to treat multiple solid tumors. It has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company has research collaboration with WuXi Biologics to design and co-research TCR-guided T Cell engagers (TCR-TCEs) for the treatment of difficult-to-treat tumors. Medigene AG was founded in 1994 and is headquartered in Munich, Germany.

Compare MDG2 to Peers and Sector

Metrics to compare
MDG2
Peers
Sector
Relationship
P/E Ratio
−1.5x−2.8x−0.7x
PEG Ratio
−0.03−0.100.00
Price/Book
1.2x1.5x2.6x
Price / LTM Sales
3.1x11.8x3.1x
Upside (Analyst Target)
-329.5%46.7%
Fair Value Upside
Unlock10.1%8.1%Unlock

Earnings

Latest Release
Oct 24, 2024
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Medigene (MDG2) Stock Price Today?

The Medigene stock price today is 1.55

What Stock Exchange Does Medigene Trade On?

Medigene is listed and trades on the Vienna stock exchange.

What Is the Stock Symbol for Medigene?

The stock symbol for Medigene is "MDG2."

What Is the Medigene Market Cap?

As of today, Medigene market cap is 23.37M.

What is Medigene Earnings Per Share?

The Medigene EPS is -1.26.

What Is the Next Medigene Earnings Date?

Medigene will release its next earnings report on 25 Mar 2025.

From a Technical Analysis Perspective, Is MDG2 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.